Careium (CARE) Q2 2026 earnings summary

Executive summary

• Net sales grew 24.3% year-over-year to SEK 251.3m in Q2 2026, with organic growth of 25.6% adjusted for currency effects and growth in all regions.

• Product sales increased 33.5% to SEK 72.4m and service sales rose 21.0% to SEK 178.9m.

• Recurring revenue base strengthened, with alarm receiving centre connections up 6.1% to 343,600.

• Margin pressure from onboarding new contracts in Norway and the UK, but EBIT margin improved to 6.0%.

• New CEO Tove Christiansson appointed June 1, 2026.

Financial highlights

• Operating profit (EBIT) increased 51.3% to SEK 15.1m, with an EBIT margin of 6.0%.

• Profit for the period rose 66.0% to SEK 10.7m, EPS SEK 0.41.

• Gross margin at 42.5% (43.3%), with margin pressure from low-margin installations.

• Free cash flow increased to SEK 4.7m (1.0m last year); cash at quarter-end SEK 40.3m.

• Net debt decreased to SEK 166.5m (178.3m); equity ratio 64.5%.

Outlook and guidance

• Focus on building a modern, unified European health-tech company with scalable technology.

• Prioritizing continuous improvements for scalable and profitable growth across all markets.

• No financial guidance provided.